This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siva, A. C. Articles by Xin, H. Search for Related Content PubMed PubMed Citation Articles by Siva, A. C. Articles by Xin, H.

Targeting CUB Domain-Containing Protein 1 with a Monoclonal Antibody Inhibits Metastasis in a Prostate Cancer Model

Alexion Antibody Technologies, Inc., San Diego, California

Requests for reprints: Katherine S. Bowdish, Anaphore, Inc., 9393 Towne Center Drive, Suite 120, San Diego, CA 92121. Phone: 858-587-4815; E-mail: kbowdish{at}anaphoreinc.com.

Key Words: CDCP1 • cell migration • immunotoxin • tumorigenicity • metastasis • saporin

Through a whole-cell panning approach, we previously identified a panel of antibodies that bound to prostate cancer cell surface antigens. One such antigen, CUB domain-containing protein 1 (CDCP1), was recognized by monoclonal antibody 25A11 and is a single transmembrane molecule highly expressed in several metastatic cancers as well as on CD34⁺CD133⁺ myeloid leukemic blast cells. We show CDCP1 expression on prostate cancer cell lines by real-time quantitative PCR (RT-qPCR), flow cytometry, and immunohistochemistry and on prostate cancer patient samples by RT-qPCR and immunohistochemical staining. In cell-based assays, antibody 25A11 inhibited prostate cancer cell migration and invasion in vitro. Further characterization showed that CDCP1 is internalized on antibody binding. When 25A11 was coupled to the cytotoxin saporin either directly or via a secondary antibody, both resulted in prostate cancer cell killing in vitro. In vivo targeting studies with an anti-CDCP1 immunotoxin showed significant inhibition of primary tumor growth as well as metastasis in a mouse xenograft model. These data provide support for continued evaluation of anti-CDCP1 therapy for potential use in cancer in primary and metastatic disease. [Cancer Res 2008;68(10):3759–66]

This article has been cited by other articles:

				D. S. Spassov, F. L. Baehner, C. H. Wong, S. McDonough, and M. M. Moasser The Transmembrane src Substrate Trask Is an Epithelial Protein that Signals during Anchorage Deprivation Am. J. Pathol., May 1, 2009; 174(5): 1756 - 1765. [Abstract] [Full Text] [PDF]